TheBodyPro: Expert analysis from Benjamin Young, M.D., Ph.D.
For HIV-treating clinicians of a certain age, the term “lipodystrophy” probably conjures a complex mish-mash of memories: atypically large abdomens and necks; atypically thin limbs, buttocks, and faces; and a significant amount of frustration and confusion among patients during a time when antiretroviral therapy was otherwise working immunological miracles.
In some very significant ways, we are treating a very different HIV epidemic these days than we were back then. But as a new study out of Washington, D.C., informs us, lipodystrophy remains a real and present issue among our patients today — both as a legacy matter and as a still-emerging concern with a significant impact on other comorbidity risks.
Read the full analysis here.